

# Program Book Addendum

## STSA 65th Annual Meeting Program Changes

Unless otherwise noted in this addendum or verbally by speakers, participants have no relevant financial or regulatory relationships to disclose. Participants listed with a **D** next to their name have indicated that they do have a financial and/or regulatory disclosure and that disclosure is listed immediately below their name.

### PRESENTER CHANGES

FIRST SCIENTIFIC SESSION (Thursday | Nov. 8 | 9:30 am – 9:45 am)

**7. The Efficacy of Re-Resection is Superior to Non-Surgery for Recurrence/ Second Primary Lung Cancer After Initial Curative Treatment**

**Xiaozheng Kang**, *Peking University Cancer Hospital, Beijing, China*

FOURTH SCIENTIFIC SESSION A: Congenital Breakout (Friday | Nov. 9 | 7:30 am – 7:45 am)

**37. Outcomes in Management of Neonatal Distal Aortic Arch Hypoplasia With Coarctation**

**\*Kirk R. Kanter**, *Emory University, Atlanta, GA*

FOURTH SCIENTIFIC SESSION B: Congenital Breakout (Friday | Nov. 9 | 9:30 am – 9:45 am)

**51. Factors Associated With Survival Following Extracorporeal Cardiopulmonary Resuscitation in Children**

**Nicholas Melvan**, *Emory University School of Medicine, Atlanta, GA*

### DISCUSSANT CHANGES

FOURTH SCIENTIFIC SESSION B: Congenital Breakout (Friday | Nov. 9 | 9:15 am – 9:30 am)

**50V. Surgical Treatment of Biventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy**

**Discussant: \*Jeffrey P. Jacobs**, *Johns Hopkins All Children's Hospital, St. Petersburg, FL*

FOURTH SCIENTIFIC SESSION C: Congenital Breakout (Friday | Nov. 9 | 11:00 am – 11:15 am)

**61. Comprehensive Valve Program in Patients With Congenital Heart Disease Undergoing Re-Entry Right Ventricular Outflow Tract Intervention in the Transcatheter Era: Review of Outcomes and Cost Analysis**

*No Discussant—Presenter will be allotted 7 minutes, followed by 8 minutes of open discussion with the audience.*

### MODERATOR CHANGES

FOURTH SCIENTIFIC SESSION C: Adult Cardiac Breakout (Friday | Nov. 9 | 11:00 am – 12:00 pm)

**\*George J. Arnaoutakis**, *University of Florida, Gainesville, FL*

FOURTH SCIENTIFIC SESSION C: Congenital Breakout (Friday | Nov. 9 | 11:00 am – 12:00 pm)

**\*Jeffrey P. Jacobs**, *Johns Hopkins All Children's Hospital, St. Petersburg, FL*

### INSTITUTION CHANGES

FOURTH SCIENTIFIC SESSION A: Thoracic Breakout (Friday | Nov. 9 | 8:15 am – 8:30 am)

**34V. Robotic Assisted Retrosternal Thyroidectomy**

**Ray K. Chihara**, *Houston Methodist Hospital, Houston, TX*

FOURTH SCIENTIFIC SESSION C: Congenital Breakout (Friday | Nov. 9 | 11:15 am – 11:30 am)

**62. Role of Pulmonary Valve Z-Score in Valve-Sparing Surgical Repair of Tetralogy of Fallot - Systematic Review**

**\*Raina Sinha**, *University of Texas Health Science Center at Houston, Houston, TX*

**Vasu Gooty**, *University of Texas Southwestern Dallas, Dallas, TX*

# Program Book Addendum

---

Thanks to *Gold* Corporate Supporter,  
**Edwards Lifesciences**

Thanks to *Silver* Corporate Supporter,  
**Mallinckrodt Pharmaceuticals**

---

## ADDITIONAL EXHIBITORS

### **Abbott Structural Heart**

Alpharetta, GA 30022

Abbott Structural Heart is a leader in Cardiovascular Devices. Our products include Trifecta Aortic Valves, Epic Mitral Valves, Regent Aortic Mechanical Valves, Mitraclip, and Amplatzer closure devices.

**Booth: 110**

### **ABIOMED**

Danvers, MA 01923

Abiomed is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. CEO, Chairman, and President Michael R. Minogue has focused the company's efforts on developing ground-breaking technologies designed to improve the patient outcomes focused on native heart recovery. Founded in 1981 for the purpose of developing the world's first artificial heart, Abiomed has remained dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

**Booth: 2**

### **Astute Medical, Inc.**

San Diego, CA 92121

Gauge the risk of acute kidney injury before damage occurs with NephroCheck® in patients who currently have or have had within the past 24 hours acute cardiovascular and/or respiratory compromise.

**Booth: 117**

### **Auris Health**

Redwood City, CA 94065

The Monarch Platform integrates the latest advancements in robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform to improve outcomes and reduce cost. The first disease in our sight is lung cancer.

**Booth: 115**

### **LivaNova**

Houston, Texas 77058

As a global leader in cardiac surgery, our advanced solutions have made significant contributions to open-heart surgery outcomes for many patients. Our devices and systems are used in more than 50% of open-heart surgery procedures worldwide. The work doesn't stop there. Our global R&D centers are powered by scientists driven to find smarter and more affordable solutions to treat heart conditions. Through our commitment to continuous training and education, we're responsive to the needs of patients, physicians, hospitals, and healthcare stakeholders.

**Booth: 206**

### **Pacira Pharmaceuticals, Inc.**

Parsippany, NJ 07054

Our in-depth knowledge of the postsurgical pain market, coupled with our passion for delivering improved patient care, drives our commitment to providing solutions that address unmet medical needs and improve clinical results.

**Booth: 106**

# Program Book Addendum

---

## ADDITIONAL EXHIBITORS *continued*

### **The Thoracic Surgery Foundation**

**Booth: 6**

Chicago, IL 60611

TSF was first established in 1988 as a 501(c)(3) not-for-profit charitable organization. The TSF Board of Directors was composed of members of the four leading thoracic surgery societies: AATS, STS, STSA, and WTSA. On October 1, 2014, TSF became the charitable arm of The Society of Thoracic Surgeons. The mission of TSF is to foster the development of surgeon scientists in cardiothoracic surgery; increasing knowledge and innovation to benefit patient care.

### **Wexler Surgical**

**Booth: 116**

Houston, Texas 77035

Wexler Surgical designs and manufactures a variety of titanium and stainless steel specialty surgical instruments and products for Cardiac, Vascular, Thoracic, and Micro Surgery. Come see our VATS/MICS instruments and ask about our Optimus Series. Visit us online at [www.wexlersurgical.com](http://www.wexlersurgical.com) for more information about our products and services.

### **ZipperBelt**

**Booth: 214**

Dallas, TX 75205

The ZipperBelt® provides sternal support and pain relief for patients following sternotomy. Studies have shown that post surgical support of the sternum can help patients recover more quickly and avoid post-surgical complications.

---

## 65th Annual Meeting Scientific Paper Corrections

*Corrected title for abstract #72 is as follows. All other abstract information as published in the Program Book is accurate. Download the complete Program Book at [www.stsa.org](http://www.stsa.org) or the new STSA Mobile Application in the Google Play or Apple App Store.*

FIFTH SCIENTIFIC SESSION (Friday | Nov. 9 | 4:00 pm – 4:15 pm)

### **72. Incidence and Predictors of Isolated Brain Metastases After Curative Resection for Esophageal Cancer**

**Presenting Author:** *Tamar B. Nobel, Memorial Sloan Kettering Cancer Center; Mount Sinai Hospital, New York, NY*

*Reference page 212 for additional abstract information.*

---

## DISCLOSURE UPDATES

FOURTH SCIENTIFIC SESSION C: Surgical Transcatheter Interventions Breakout (Friday | Nov. 9 | 11:45 am – 12:00 pm)

### **68. Does the Integrated Risk Assessment by the Heart Team Predict Outcomes After Transcatheter Aortic Valve Replacement (TAVR)?**

**Discussant:** *D\*Danny Chu, UPMC Heart & Vascular Institute, Pittsburgh, PA*

**Commercial Relationships:** Consultant/Advisory Board: Japanese Organization for Medical Device Development, Inc.; The Osler Institute; Quality Insights, Inc.; Terumo Cardiovascular Systems Corp.; Wolters Kluwer Health